Generate Biomedicines, Inc. Common Stock (GENB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Generate Biomedicines, Inc. Common Stock (GENB) has a cash flow conversion efficiency ratio of -0.156x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-80.39 Million) by net assets ($514.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Generate Biomedicines, Inc. Common Stock balance sheet quality to measure how much of total assets are equity-financed.
Generate Biomedicines, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Generate Biomedicines, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how well can Generate Biomedicines, Inc. Common Stock service its debt to assess how comfortably operating cash covers total debt obligations.
Generate Biomedicines, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Generate Biomedicines, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Airport City Ltd
TA:ARPT
|
0.013x |
|
Honasa Consumer Limited
NSE:HONASA
|
0.000x |
|
Harbin Hatou Investment Co Ltd
SHG:600864
|
0.090x |
|
Mister Car Wash, Inc. Common Stock
NYSE:MCW
|
0.083x |
|
Dno ASA
OL:DNO
|
0.225x |
|
Wuxi Online Offline Communication Information Technology Co. Ltd.
SHE:300959
|
N/A |
|
Tongyu Heavy Industry
SHE:300185
|
0.004x |
|
Kfin Technologies Limited
NSE:KFINTECH
|
0.108x |
Annual Cash Flow Conversion Efficiency for Generate Biomedicines, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Generate Biomedicines, Inc. Common Stock from 2024 to 2025. For the full company profile with market capitalisation and key ratios, see Generate Biomedicines, Inc. Common Stock (GENB) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-623.20 Million | $-200.62 Million | 0.322x | +18.95% |
| 2024-12-31 | $-435.09 Million | $-117.75 Million | 0.271x | -- |
About Generate Biomedicines, Inc. Common Stock
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is … Read more